WO2022184547A1 - Utilisation de fructanes pour fournir des bénéfices de soin cutané - Google Patents

Utilisation de fructanes pour fournir des bénéfices de soin cutané Download PDF

Info

Publication number
WO2022184547A1
WO2022184547A1 PCT/EP2022/054673 EP2022054673W WO2022184547A1 WO 2022184547 A1 WO2022184547 A1 WO 2022184547A1 EP 2022054673 W EP2022054673 W EP 2022054673W WO 2022184547 A1 WO2022184547 A1 WO 2022184547A1
Authority
WO
WIPO (PCT)
Prior art keywords
fructans
human
acid
species
skin
Prior art date
Application number
PCT/EP2022/054673
Other languages
English (en)
Inventor
Michael John Hoptroff
Joanne Elizabeth HUNT
Barry Murphy
Emily Grace SMITH
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Priority to EP22706637.0A priority Critical patent/EP4301328A1/fr
Publication of WO2022184547A1 publication Critical patent/WO2022184547A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to the use of fructans for providing skin care benefits by supporting the growth of beneficial commensal microbial species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome.
  • An objective of the present invention is to provide skin care benefits by supporting the growth of beneficial commensal microbial species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome.
  • the invention provides the cosmetic use of fructans in a topical skin care composition as an active ingredient for providing skin care benefits by supporting the growth of beneficial commensal microbial species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome, characterised in that the beneficial commensal microbial species are Streptococcus species.
  • the invention also provides fructans, for use in supporting the growth of beneficial commensal Streptococcus species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome.
  • the invention also provides the use of fructans in, and for the manufacture of, topical compositions for supporting the growth of beneficial commensal Streptococcus species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome.
  • skin is understood as the layers which comprise it, from the uppermost layer or stratum corneum to the lowermost layer or hypodermis, both inclusive. These layers are composed of different types of cells such as keratinocytes, fibroblasts, melanocytes, mastocytes, neurons, and adipocytes. The term “skin” also comprises the scalp.
  • infant refers in general to a human baby or young child from birth up to about 5 years of age, such as from birth up to about 3 years of age and preferably from birth up to about 1 year of age.
  • Infant skin is structurally different to adult skin; the cells are smaller, and the collagen fibres are thinner. According to clinical findings, infant stratum corneum is 30% thinner than in adults, and infant epidermis is 20% thinner than in adults.
  • the composition of infant skin is also different from that of adult skin, containing less natural moisturising factors (NMFs), less lipids and less melanin. Infant skin also has a higher pH than adult skin. These differences in structure and composition lead to differences in the function of the skin as a barrier.
  • One of the main measurements of skin barrier is the rate of trans epidermal water loss (TEWL). Infant skin has a higher rate of TEWL than adult skin. Studies show that TEWL rates are highest in younger infant age groups (3 to 6 months old) and continue to show higher levels than adult skin through the first year of life.
  • skin care means regulating and/or improving cosmetic qualities of the skin, (as opposed to curing, treating, or preventing a disease or disorder). Accordingly, such cosmetic qualities are subject to regulation and/or improvement both in healthy subjects as well as those which present diseases or disorders of the skin (such as psoriasis, lichen planus, folliculitis or atopic dermatitis).
  • Examples of skin care benefits in the context of this invention include providing a smoother, more even texture; improving the elasticity or resiliency of the skin; improving the firmness of the skin; improving the hydration status or moisturization of the skin; improving skin barrier properties; and reducing the appearance of redness or skin blotches.
  • fructans are used for supporting the growth of beneficial commensal Streptococcus species which are resident in the human cutaneous microbiome, in particular the human infant cutaneous microbiome.
  • VGS beneficial commensal Streptococcus species in the context of this invention are bacteria of the viridans group of streptococci (VGS).
  • VGS are a group of catalase negative, Gram-positive cocci with a chaining morphology on microscopic examination. They are leucine aminopeptidase positive, pyrrolidonylarylamidase negative, and do not grow in 6.5% NaCI, and almost all species are negative for growth on bile esculin agar.
  • VGS can be differentiated from Streptococcus pneumoniae in that they are optochin-resistant and are not bile soluble; they also lack either the polysaccharide-based capsule typical of S.
  • VGS The salivarius group of VGS consists of three genetically similar species: Streptococcus salivarius, Streptococcus vestibularis and Streptococcus thermophilus (also known as Streptococcus salivarius subsp. thermophilus). S.
  • thermophilus is classified as a lactic acid bacterium, and is believed to have developed separately from pathogenic Streptococcus species for at least 3000 years. Its genome sequence does not contain any of the virulence regions common to pathogenic species of Streptococcus. Streptococcus thermophilus has been observed to increase the level of ceramides in stratum corneum in vitro and in vivo. Ceramides are the major lipid constituent of lamellar sheets present in the intercellular spaces of the stratum corneum, which are thought to provide the barrier property of the epidermis.
  • Streptococcus thermophilus cream in patients with atopic dermatitis led to a significant improvement in erythema, scaling and pruritus. It has also been suggested that Streptococcus thermophilus can inhibit Staphylococcus aureus growth by producing hydrogen peroxide; and certain strains of Streptococcus thermophilus have been shown to produce exosaccharide polymers including hyaluronic acid.
  • a fructan is understood to mean any oligo- or polysaccharide that contains at least two adjacent fructose units linked by fructosyl-fructose glycosidic bonds.
  • Fructans can have at least one fructosyl-glucose glycosidic bond, as in sucrose, which when present is typically a starting link in the oligomer or polymer chain. The presence of this sucrose sugar unit is not a necessary precondition for the compound to be considered a fructan; therefore, many fructans begin with fructose.
  • fructans can be linear or branched.
  • Fn An individual fructan having a glucose molecule preceding fructose is designated as GFn with G referring to the terminal glucose unit, F referring to fructose units, and n designating the number of fructose units found in the fructan chain.
  • G referring to the terminal glucose unit
  • F referring to fructose units
  • n designating the number of fructose units found in the fructan chain.
  • a fructan with no glucose would be designated as Fn.
  • Fructans can also be described by degree of polymerization (DP).
  • DP refers to the number of repeat units in an oligomer or polymer chain, so the DP of an individual fructan would be its number of repeating fructose units and identical to n in the designations above.
  • fructans are found in c.15% of angiosperms as well as in fungi and bacteria. They are built up by adding fructofuranosyl units to three basic trisaccharides (1-kestotriose, 6- kestotriose, and 6G-kestotriose), which themselves are synthesized by linking a fructose moiety to one of the three primary hydroxyl groups of sucrose.
  • 1-kestotriose is formed from the union of fructose to C1 of the fructose of sucrose, constituting a b-(2,1) glycosidic bond.
  • 6-kestotriose is formed from the union of fructose to C6 of the fructose of sucrose, constituting a b-(2,6) glycosidic bond.
  • 6G-kestotriose also termed neokestose
  • the initial fructose is bound to C6 of the glucose residue of sucrose, linked by a b-(2,6) glycosidic bond.
  • further elongation occurs from the fructose residues, linked by b- (2,1) and/or b-(2,6) glycosidic bonds.
  • fructans can be classified into several distinct groups. Inulins are based on 1-kestotriose and consist of linear chains of fructose units linked by b-(2,1) fructosyl-fructose glycosidic bonds. A glucose molecule typically resides at the end of each fructose chain and is linked by an a-(1,2) glycosidic bond, as in sucrose.
  • Inulins are usually found in dicot species belonging to the Asteraceae, with the main plant sources including taproots and tubers in Jerusalem artichoke ( Helianthus tuberosus), dahlia ( Dahlia pinnata), chicory ( Cichorium intybus ), elecampane ( Inula helenium), dandelion ( Taraxacum officinale), murnong ( Microseris lanceolata), salsify ( Tragopogon porrifolius), and yacon ( Polymnia sonchi folia).
  • Jerusalem artichoke Helianthus tuberosus
  • dahlia Dahlia pinnata
  • chicory Cichorium intybus
  • elecampane Inula helenium
  • dandelion Taraxacum officinale
  • murnong Microseris lanceolata
  • salsify Tragopogon porrifolius
  • yacon Poly
  • Levans are based on 6-kestotriose and consist of linear chains of fructose units linked by b-(2,6) fructosyl-fructose glycosidic bonds. Levans are produced by bacteria but can also be found in the stems and leaf bases of Poaceae monocots such as crested wheatgrass (Agropyron cristatum), orchardgrass (Dactylis glomerata), and big bluegrass ( Poa secunda). Graminans are branched fructans containing both b-(2,1) and b-(2,6) glycosidic bonds.
  • fructans are usually found in Poaceae monocots, particularly cereals such as oats (Avena sativa), wheat (Triticum aestivum) and barley (Hordeum vulgare).
  • the neoseries fructans are based on 6G-kestotriose (neokestose), with an internal glucose moiety between two fructosyl subunits which are linked to C1 and C6 on the glucose moiety respectively.
  • the inulin neoseries have b-(2, 1)-linked fructosyl residues on either end of the glucose moiety of the sucrose molecule; and the levan neoseries have b-(2, 1 )-linked and b-(2,6)- linked fructosyl residues on either end of the glucose moiety of the sucrose molecule.
  • Neoseries fructans have been found in Allioideae, Asparagaceae and Poaceae monocots such as blue agave (Agave tequilana), asparagus (Asparagus officinalis), red squill (Drimia maritima), onion (Allium cepa), garlic, (Allium sativum), oats (Avena sativa) and perennial ryegrass (Lolium perenne).
  • Fructans for use in the invention can be extracted from a natural source such as those described above, or synthesized from a more fundamental molecule (typically sucrose).
  • the products obtained usually consist of a mixture of fructan molecules of varying DP, with oligomer and/or polymer chain size and size distribution depending on the source, the harvesting conditions (where applicable) and the processing conditions.
  • High performance anion exchange chromatography (HPAEC) with pulsed amperometric detection can be used to determine the number average degree of polymerization (DP n ).
  • fructan for use in the invention include inulins consisting of linear chains of fructose units linked by b-(2,1) fructosyl-fructose glycosidic bonds.
  • Inulins suitable for use in the invention can be extracted from a natural source such as chicory ( Cichorium intybus ) roots, typically by using a hot water diffusion process.
  • the extract so obtained is generally a mixture of inulins of both GFn and Fn types with a DP n of about 10 to 12 and a distribution of chain lengths ranging from 2 to 60 b-(2,1) linked fructofuranosyl units.
  • the extract may, for example, be partially enzymatically hydrolysed.
  • the product so obtained is generally a mixture of inulins of both GFn and Fn types with a DP n of about 3 to 4 and a distribution of chain lengths ranging from 2 to 10 b-(2,1) linked fructofuranosyl units. This type of inulin is also termed oligofructose.
  • GF2 1-kestotriose
  • GF3 1,1- kestotetraose
  • GF4 1,1,1-kestopentaose
  • F2 inulobiose
  • F3 inulotriose
  • F4 inulotetraose
  • Physical separation techniques may also be used which make use of the solubility difference of the DP fractions present in extracts. For example, techniques such as ultrafiltration, crystallisation and solvent precipitation can be used to remove oligomers with a DP less than 10.
  • the product so obtained is generally a mixture of inulins of both GFn and Fn types with a DP n of about 20 to 30 and a distribution of chain lengths ranging from 10 to 60 b-(2,1) linked fructofuranosyl units).
  • Inulins suitable for use in the invention can also be produced enzymatically.
  • the starting molecule used is typically sucrose, and the inulin is synthesized from the sucrose by transfructosylation. This is usually accomplished by means of an enzyme, b- fructofuranosidase, which is obtainable from fungal strains, especially those from the Aspergillus genus (e.g. Aspergillus niger).
  • the enzyme activity sequentially adds fructose units with new b-(2,1) glycosidic bonds placed in the chain.
  • the glucose and fructose molecules formed as by-products of the process, as well as any unreacted sucrose may be removed with the use of chromatography.
  • the product so obtained is generally a mixture of inulins of GFn type with a DP n of about 3.6 and a distribution of chain lengths ranging from 2 to 4 b-(2,1) linked fructofuranosyl units).
  • This type of inulin is also termed fructooligosaccharides (FOS). It is composed primarily of oligosaccharides such as 1-kestotriose (GF2), 1,1-kestotetraose (GF3) and 1 ,1 ,1-kestopentaose (GF4).
  • compositions for use in the invention can be formulated in a variety of forms for topical application, and will generally contain from about 0.01 to about 10%, preferably from about 0.1 to about 5% of fructan (by weight based on the total weight of the composition).
  • Topical compositions for use in the invention will generally include a cosmetically acceptable vehicle.
  • Cosmetically acceptable means that the vehicle is suitable for topical application to the skin, has good aesthetic properties, is compatible with the fructan and any other ingredients, and will not cause any safety or toxicity concerns.
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase, or a mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams, and heavy creams.
  • Exemplary emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, polyol-in-silicone emulsions, silicone-in-polyol emulsions, polyol-in-oil emulsions, oil-in-polyol emulsions, wax-in-water emulsions and water-oil-water triple emulsions.
  • Preferred emulsions include oil-in-water emulsions and water-in-oil emulsions.
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
  • Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of glycols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl oleate
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention typically have an aqueous phase, with the amount of water in such an emulsion suitably ranging from about 5 to about 95%, preferably from about 35 to about 80% (by weight based on the total weight of the composition).
  • the aqueous phase may also include one or more organic liquids that are miscible with water at room temperature (25°C).
  • Exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C2-C6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3-C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C 1 -C 4 ) alkyl ethers and mono-, di-, or triethylene glycol (C 1 -C 4 ) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
  • C2-C6 alkanols such as ethanol and isopropanol
  • C2-C10 glycols and polyols such as glycerol, propylene glycol, butylene glyco
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention generally include emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
  • the amount of emulsifier and solubilizer in such an emulsion suitably ranges from about 0.1 to about 30%, preferably from about 1 to about 8% (by weight based on the total weight of the composition).
  • Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3-diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, cetyl phosphate, di
  • Topical cosmetic compositions suitable for use in the invention may also take the form of a skin cleanser incorporating one or more cleansing surfactants which, when combined with water and mechanically agitated, generate a foam or lather.
  • the amount of cleansing surfactant suitably ranges from about 5 to about 40%, preferably from about 10 to about 35% (by weight based on the total weight of the composition).
  • Exemplary cleansing surfactants include anionic surfactants such as ammonium lauroyl sarcosinate, sodium trideceth sulfate, sodium lauroyl sarcosinate, sodium myristoyl sarcosinate, ammonium laureth sulfate, sodium laureth sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium cocoyl glycinate, sodium lauroyl glycinate, sodium lauroyl taurate, sodium methyl lauroyl taurate, sodium methyl oleoyl taurate, sodium cetyl sulfate, sodium lauroyl lactylate and triethanolamine lauroyl lactylate and mixtures thereof; nonionic surfactants such as lauramine oxide, cocoamine oxide, decyl polyglucose,
  • Topical cosmetic compositions for use in the invention may also be formulated in a single phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • a single phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • Topical cosmetic compositions for use in the invention may also be formulated in solid forms such as gels or sticks.
  • a topical cosmetic composition for use in the invention may include additional skin care actives (for improving the physical and/or aesthetic characteristics of the skin).
  • additional skin care actives which are suitable for use in the invention include vitamins, minerals and/or antioxidants, emollients, humectants, skin anti hyperpigmentation agents, sunscreens, anti-irritants, exfoliating agents, and mixtures thereof.
  • Vitamins, minerals and/or antioxidants suitable for use in the invention include natural botanical antioxidants derived from plant materials such as fruits, vegetables, herbs and spices (such as goji berry, white tea, rosemary, green tea, grape seed and lemongrass extracts); vitamin A and its precursors or derivatives (such as beta-carotene, retinyl palmitate); vitamin B3 and its precursors or derivatives (such as niacinamide); vitamin B5 and its precursors or derivatives (such as panthenol and its precursors or derivatives); vitamin C and its precursors or derivatives (such as tetrahexyldecyl ascorbate, ascorbyl palmitate); vitamin E and its precursors or derivatives (such as d-alpha-tocopherol, tocopheryl acetate); vitamin K and its precursors or derivatives; selenium and its derivatives (such as L-selenomethionine); and alpha lipoic acid.
  • natural botanical antioxidants derived from plant materials such as fruits, vegetables,
  • Emollients suitable for use in the invention act to increase and maintain moisture in the skin by providing a protective coating to impede epidermal water loss.
  • emollients include C10-20 fatty alcohols and acids (such as cetyl, myristyl, palmitic and stearyl alcohols and acids); and C10-40 hydrocarbons (such as mineral oil, petroleum jelly, squalene and isoparaffins).
  • Humectants suitable for use in the invention act to increase and maintain moisture in the skin by attracting water to the stratum corneum of the epidermis.
  • humectants include amino acids, chondroitin sulfate, glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4- butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, erythritol, fructose, glucose, maltose, sucrose, lactose, xylose, inositol, lactitol, xylitol, sorbitol, mannitol, maltitol, panthenol, pentaeryth
  • Skin anti-hyperpigmentation agents suitable for use in the invention include natural botanical agents derived from plant materials (such as Arctostaphylos patula and Arctostaphylos viscida extracts, Emblica officinalis extract, Mitracarpus scaber extract, Uva ursi (bearberry) extract, Morns bombycis (mulberry) extract, Morns alba (white mulberry) extract, Broussonetia papyrifera (paper mulberry) extract, licorice extract, acerola cherry extract, Chlorella vulgaris extract, Aloe ferrox extract and Rumex occidentalis extract); synthetic or natural sugar amines (such as glucosamine, N-acetyl glucosamine, glucosamine sulfate, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine and their hydrochloride salts); retinoids (such as retinol, retinal
  • Sunscreens suitable for use in the invention protect the skin from ultraviolet (UV) solar radiation falling within both the UVB region (between 290nm to 320 nm wavelengths) and the UVA region (between 320nm and 400nm wavelengths).
  • sunscreens include methoxycinnamate derivatives (such as octyl methoxycinnamate and isoamyl methoxycinnamate); camphor derivatives (such as 4-methyl benzylidene camphor, camphor benzalkonium methosulfate, and terephthalylidene dicamphor sulfonic acid); salicylate derivatives (such as octyl salicylate and homosalate); sulfonic acid derivatives (such as phenylbenzimidazole sulfonic acid); benzone derivatives (such as dioxybenzone, sulisobenzone, and oxybenzone); benzoic acid derivatives (such as aminobenzoic acid and octyld
  • Anti-irritants suitable for use in the invention include allantoin, aloe vera, a-bisabolol, caffeine, chamomile extract, Cola nitada extract, cucumber extract, dipotassium glycyrrhizinate, glycyrrhizic acid, green tea extract, lecithin or hydrogenated lecithin, licorice extract, Avena sativa (oat) meal extract, tea tree oil, salicylic acid, acetylsalicylic acid, strontium acetate, strontium chloride, strontium nitrate, fatty acids with anti-irritant properties (such as linoleic acid and linolenic acid) and aromatic aldehydes with anti-irritant properties (such as 4-methoxy benzaldehyde, 4-ethoxy benzaldehyde, 4-butoxy benzaldehyde and 4- pentoxy benzaldehyde).
  • Exfoliating agents suitable for use in the invention include benzoyl peroxide, benzoic acid, 3- hydroxy benzoic acid, salicylic acid, acetic acid, trichloroacetic acid, 1-pyrrolidone-5- carboxylic acid, a-hydroxy acids (such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid); b-hydroxy acids (such as b-hydroxybutyric acid); a-keto acids (such as pyruvic acid, 2-oxopropanoic acid, 2-oxobutanoic acid and 2-oxopentanoic acid); and oxa acids (such as 3,6,9-trioxaundecanedioic acid). Mixtures of any of the above described materials may also be used.
  • a-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid
  • b-hydroxy acids such as b-hydroxybutyric acid
  • a-keto acids such as
  • a topical cosmetic composition for use in the invention may include additional functional ingredients (for improving the physical and/or aesthetic characteristics of the composition).
  • water soluble or colloidally water soluble polymeric thickening agents such as hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, cross-linked polyacrylate polymers and polyacrylamide polymers
  • structurant clays such as magnesium aluminum silicate, attapulgite, bentonite, montmorillonite and hectorite
  • inorganic pigments such as titanium oxide, zirconium oxide, cerium oxide zinc oxide, iron oxide, chromium oxide and ferric blue
  • organic pigments such as carbon black and barium, strontium, calcium, and aluminium lakes
  • pearlescent agents such as mica coated with titanium oxide and/or iron oxide
  • dyes, preservatives such as hydroxyethyl cellulose, methyl
  • a topical cosmetic composition for use in the invention may be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or a cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • the composition is suitably applied to the skin, preferably infant skin, at the rate of one or two applications per day.
  • an amount corresponding to about 1 to 2 ml of the composition per application is applied uniformly over the area of treatment twice daily for a period of at least 7 (seven) days, more preferably at least 30 (thirty) days.
  • fructans were evaluated for their ability to enhance growth and acid production of various commensal species of Streptococcus. Stock solutions of the test fructans were prepared such that upon dilution the concentrations in test would range from 2% to 0.07%.
  • Test bacterial inoculums were prepared in culture media for 18 hours at 37 °C under C0 2 conditions. Inoculums were centrifuged and resuspended in liquid media diluted to 50% in sterile distilled water. The inoculums were adjusted to a cell density of 1.5-5 x 10 s CFU/ml.
  • microtiter plate was incubated without shaking at 37 °C for 24 hours and an endpoint optical density read taken at 620 nm.
  • the HydroPlate® was read kinetically for fluorescence for 24 hours at 37°C.
  • PreSens calibration software pHSolver_v10 was used as part of the analysis.
  • Table 1 shows the endpoint optical density of the tested bacterial species after incubation with the test fructans, compared to the growth control.
  • Table 2 shows the calculated acid produced by the tested bacterial species after incubation with the test fructans, compared to the growth control.
  • Table 2 The following Table 3 shows the endpoint optical density and calculated acid produced when S. thermophilus (ATCC® 19258TM) is incubated with different concentrations of Prebiulin AGA, compared to the growth control. Table 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique de fructanes dans une composition de soin cutané topique comme ingrédient actif pour fournir des bénéfices de soin cutané en soutenant la croissance d'espèces microbiennes commensales bénéfiques qui résident dans le microbiome cutané humain, en particulier le microbiome cutané de l'enfant humain, caractérisé en ce que les espèces microbiennes commensales bénéfiques sont des espèces de Streptococcus.
PCT/EP2022/054673 2021-03-04 2022-02-24 Utilisation de fructanes pour fournir des bénéfices de soin cutané WO2022184547A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22706637.0A EP4301328A1 (fr) 2021-03-04 2022-02-24 Utilisation de fructanes pour fournir des bénéfices de soin cutané

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21160819 2021-03-04
EP21160819.5 2021-03-04

Publications (1)

Publication Number Publication Date
WO2022184547A1 true WO2022184547A1 (fr) 2022-09-09

Family

ID=74859212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/054673 WO2022184547A1 (fr) 2021-03-04 2022-02-24 Utilisation de fructanes pour fournir des bénéfices de soin cutané

Country Status (2)

Country Link
EP (1) EP4301328A1 (fr)
WO (1) WO2022184547A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202136A1 (en) * 2012-02-14 2015-07-23 The Procter & Gamble Company Topical use of a skin-commensal prebiotic agent and compositions containing the same
FR3081709A1 (fr) * 2018-05-29 2019-12-06 Lilas 3 Composition topique sterile pour utilisation chez les nouveau-nes pour maintenir, reguler et normaliser le microbiote cutane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202136A1 (en) * 2012-02-14 2015-07-23 The Procter & Gamble Company Topical use of a skin-commensal prebiotic agent and compositions containing the same
FR3081709A1 (fr) * 2018-05-29 2019-12-06 Lilas 3 Composition topique sterile pour utilisation chez les nouveau-nes pour maintenir, reguler et normaliser le microbiote cutane

Also Published As

Publication number Publication date
EP4301328A1 (fr) 2024-01-10

Similar Documents

Publication Publication Date Title
US11865373B2 (en) Topical skin care formulations comprising plant extracts
US20090156563A1 (en) Glucan Compositions
KR20150103138A (ko) 안티에이징용 피부 외용 조성물 및 그 제조방법
US8747927B2 (en) Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof
CN106535874B (zh) 毛孔缩小剂
JP2012184270A (ja) 皮膚外用剤
KR101641702B1 (ko) 신규 유사세라마이드 화합물 및 이를 포함하는 조성물
JP5683134B2 (ja) 皮膚外用剤
TW200529879A (en) Anti-aging composition and collagen production promoting composition
JP2022537463A (ja) ビフィドバクテリウム（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ）種溶解物と、サッカロミセス（Ｓａｃｃｈａｒｏｍｙｃｅｓ）属の酵母抽出物と、単糖とを含む化粧用組成物及びその美容的使用
US10376459B2 (en) Combination of active agents comprising at least one essential oil, one cyclodextrin and one liquid fatty substance and composition comprising it
KR20190081232A (ko) 곤충(귀뚜라미)의 단백질과 산야초 추출물의 혼합물를 피부 미백, 세포재생, 보습 유효성분으로 포함하는 화장품 조성물
JP2024506865A (ja) スキンケア組成物及びその使用方法
WO2022184547A1 (fr) Utilisation de fructanes pour fournir des bénéfices de soin cutané
EP3305370A1 (fr) Activateur d'autophagie des algues
EP4301329A1 (fr) Utilisation de galacto-oligosaccharides pour procurer des bienfaits à la peau
JP6902392B2 (ja) カルボニル化抑制剤
KR102627924B1 (ko) 시린직산, 바닐릭산 및 에피카테친을 포함하는 화장료 조성물
ES2624909T3 (es) Composición para el cuidado de la piel
EP4218713A1 (fr) Utilisation d'une composition topique de soins de la peau pour améliorer la biosynthèse des lipides de la couche cornée
JP6964393B2 (ja) カルボニル化抑制剤及び糖化抑制剤
JP2013129615A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22706637

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022706637

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022706637

Country of ref document: EP

Effective date: 20231004